Arena Pharmaceuticals, Inc (NASDAQ:ARNA) is a biopharmaceutical company focused on discovering, developing and commercializing drugs that target G protein-coupled receptors. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize BELVIQ in the United States. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) stock opened at $6.70 in last session, and closed at $6.49, while the day range of stock is $6.45 – $6.75. The stock showed a negative weekly performance of -8.85%.
Wells Fargo & Co. restated their positive rating on shares of Geron Corp. (NASDAQ:GERN) in a research note issued to investors on Thursday, Analyst Ratings Network reports. Geron Corporation (NASDAQ:GERN) stock opened at $1.82, in last session and closed at $1.83, by losing 2.52%. The 52 week range of the stock is $0.98 – $7.79. Company’s market capitalization is $283.33 million.
Shares of West L.A. biotechnology firm CytRx Corp. (NASDAQ:CYTR) rebounded after falling as much as 10 percent Friday due to reports that the company has worked closely with a stock promoter to boost interest in its shares without disclosing its involvement. CytRx Corporation (NASDAQ:CYTR) stock decreased -0.48% and finished the last session at $4.15. The EPS of the stock remained -1.34. Company’s market capitalization is $230.59 million.
CEL-SCI Corporation (NYSEAMEX:CVM) announced its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection) has activated its first U.S. clinical trial expansion site at 21st Century Oncology in Greenville, North Carolina.CEL-SCI Corporation (NYSEMKT:CVM) stock opened the session at $1.44, and closed the session at $1.53. The 52 week range of the stock remained $0.53 – $3.09 and the day range was $1.35 – $1.57.